celecoxib has been researched along with Allodynia in 51 studies
Excerpt | Relevance | Reference |
---|---|---|
"To evaluate and compare the effects of salmon calcitonin (sCT) and celecoxib (CLX) on cartilage, subchondral bone and tactile allodynia in a rat model of lumbar facet joint (FJ) osteoarthritis (OA)." | 7.91 | Salmon calcitonin exerts better preventive effects than celecoxib on lumbar facet joint degeneration and long-term tactile allodynia in rats. ( Chen, T; Dai, M; Gou, Y; Kong, Q; Li, H; Lv, Q; Shao, L; Song, H; Tian, F; Zhang, L; Zhang, Y, 2019) |
"The non-steroidal anti-inflammatory drug celecoxib has long been used for reducing pain, in spite of moderate gastrointestinal side effects." | 7.85 | The Analgesic Effects of Celecoxib on the Formalin-induced Short- and Long-term Inflammatory Pain. ( Guo, XJ; Liang, JC; Sun, Y; Tang, K; Wang, HY; Wang, Y; Wang, YT; Yin, JB; Zhao, YQ, 2017) |
"Lornoxicam exhibits strong analgesic but weak antipyretic effects in rats with paw inflammation." | 7.75 | The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation. ( Arai, I; Futaki, N; Harada, M; Hashimoto, Y; Honma, Y; Hoshi, K; Nakaike, S; Sugimoto, M, 2009) |
"The purpose of this study is to clarify involvement ratios between central and peripheral cyclooxygenase (COX)-2 in rat inflammatory pain models, by evaluating celecoxib and [6-chloro-2-(4-chlorobenzoyl)-1H-indol-3-yl]acetic acid (CIAA) on carrageenan-induced mechanical and thermal hyperalgesia." | 7.74 | Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA. ( Kita, Y; Murata, Y; Okumura, T; Sakakibara, A, 2008) |
"Formalin (0." | 5.42 | Celecoxib reduces hyperalgesia and tactile allodynia in diabetic rats. ( Bermúdez-Ocaña, DY; Ble-Castillo, JL; Díaz-Zagoya, JC; Granados-Soto, V; Juárez-Rojop, IE; Morales-Hernández, PE; Torres-Lopez, JE; Tovilla-Zárate, CA, 2015) |
"The non-steroidal anti-inflammatory drug celecoxib has long been used for reducing pain, in spite of moderate gastrointestinal side effects." | 3.85 | The Analgesic Effects of Celecoxib on the Formalin-induced Short- and Long-term Inflammatory Pain. ( Guo, XJ; Liang, JC; Sun, Y; Tang, K; Wang, HY; Wang, Y; Wang, YT; Yin, JB; Zhao, YQ, 2017) |
" The compounds 3a, 3b, 3c, 3e, and 3f presented anti-hyperalgesic action, while the compounds 3a, 3c, 3d, 3f, and 3g exhibited anti-edematogenic effects, without causing locomotive disorders in animals, thus making them comparable to Celecoxib in an arthritic pain model." | 3.81 | Regioselectively controlled synthesis of 3(5)-(trifluoromethyl)pyrazolylbenzenesulfonamides and their effects on a pathological pain model in mice. ( Bonacorso, HG; Brusco, I; Canova, B; da Silva, TV; de Souza, ON; Dos Santos, JM; Lobo, MM; Machado, P; Martins, MA; Oliveira, SM; Timmers, LF; Zanatta, N, 2015) |
" These results suggest that ceftriaxone, particularly in combinations with ibuprofen, celecoxib, paracetamol, or levetiracetam, may provide useful approach to the clinical treatment of inflammation-related pain." | 3.80 | Antihyperalgesic/antinociceptive effects of ceftriaxone and its synergistic interactions with different analgesics in inflammatory pain in rodents. ( Boškovic, BD; Kovacevic, JM; Micov, AM; Stepanovic-Petrovic, RM; Tomic, MA, 2014) |
" In particular, the glycine derivative proved to be extremely active in suppressing hyperalgesia and edema." | 3.80 | Enhancing the pharmacodynamic profile of a class of selective COX-2 inhibiting nitric oxide donors. ( Alfonso, S; Anzini, M; Battilocchio, C; Biava, M; Calderone, V; Colovic, M; Consalvi, S; Di Capua, A; Di Cesare Mannelli, L; Dovizio, M; Ghelardini, C; Giordani, A; Martelli, A; Patrignani, P; Persiani, S; Poce, G; Rossi, A; Sautebin, L; Testai, L, 2014) |
" This study characterized the manner in which levetiracetam interacts with analgesics (ibuprofen, celecoxib, and paracetamol) and caffeine to suppress hyperalgesia in a model of localized inflammation." | 3.79 | Levetiracetam interacts synergistically with nonsteroidal analgesics and caffeine to produce antihyperalgesia in rats. ( Micov, AM; Stepanović-Petrović, RM; Tomić, MA, 2013) |
" Additionally, LASSBio-1135 (3a) presented activity similar to celecoxib (1) regarding the reduction of the carrageenan-induced rat paw edema (33% of inhibition at 100 micromol/kg, po)." | 3.75 | Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes. ( Barreiro, EJ; da Silva, LL; de Lima, CK; Fraga, CA; Lacerda, RB; Miranda, AL; Romeiro, NC, 2009) |
"Lornoxicam exhibits strong analgesic but weak antipyretic effects in rats with paw inflammation." | 3.75 | The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation. ( Arai, I; Futaki, N; Harada, M; Hashimoto, Y; Honma, Y; Hoshi, K; Nakaike, S; Sugimoto, M, 2009) |
"The purpose of this study is to clarify involvement ratios between central and peripheral cyclooxygenase (COX)-2 in rat inflammatory pain models, by evaluating celecoxib and [6-chloro-2-(4-chlorobenzoyl)-1H-indol-3-yl]acetic acid (CIAA) on carrageenan-induced mechanical and thermal hyperalgesia." | 3.74 | Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA. ( Kita, Y; Murata, Y; Okumura, T; Sakakibara, A, 2008) |
" This work led to the identification of 1i (4-[5-(4-methylphenyl)-3-(trifluoromethyl)- H-pyrazol-1-yl]benzenesulfonamide, SC-58635, celecoxib), which is currently in phase III clinical trials for the treatment of rheumatoid arthritis and osteoarthritis." | 3.69 | Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). ( Bertenshaw, SR; Burton, EG; Carter, JS; Cogburn, JN; Collins, PW; Docter, S; Graneto, MJ; Gregory, SA; Isakson, PC; Koboldt, CM; Lee, LF; Malecha, JW; Miyashiro, JM; Penning, TD; Perkins, WE; Rogers, RS; Rogier, DJ; Seibert, K; Talley, JJ; Veenhuizen, AW; Yu, SS; Zhang, YY, 1997) |
"To assess hyperalgesia in persistent pain patients we performed an additional analysis on patients reporting VAS>30 at 12 months." | 2.82 | Hyperalgesia and Persistent Pain after Breast Cancer Surgery: A Prospective Randomized Controlled Trial with Perioperative COX-2 Inhibition. ( Filippini-de Moor, GP; Steegers, MA; van Helmond, N; Vissers, KC; Wilder-Smith, OH, 2016) |
"Mechanical hyperalgesia, joint edema, leukocyte recruitment to the joint and damage to cartilage in experimental arthritis and cytotoxicity, spread of disease, phagocytic activity and nitric oxide (NO) and hydrogen peroxide production by macrophages were evaluated." | 1.91 | 1,4-Diaryl-1,2,3-triazole neolignan-celecoxib hybrids inhibit experimental arthritis induced by zymosan. ( B Carvalho, D; Baroni, ACM; Bonfá, IS; Candeloro, L; das Neves, AR; Felipe, JL; Ferreira, GIS; Lencina, JS; Lossavaro, PKMB; Silva-Filho, SE; Souza, MIL; Toffoli-Kadri, MC, 2023) |
"Mechanical allodynia, heat hyperalgesia, biased weight-bearing, and hindpaw thickness were assessed 0." | 1.62 | Antinociception produced by nonsteroidal anti-inflammatory drugs in female vs male rats. ( Britch, SC; Craft, RM; Hewitt, KA, 2021) |
"Pain is a prevalent PD's non-motor symptom with a higher prevalence of analgesic drugs prescription for patients." | 1.56 | Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease. ( Bortolanza, M; Crivelaro do Nascimento, G; Del Bel, EA; Ferrari, DP; Ferreira-Junior, NC; Guimaraes, FS, 2020) |
"Celecoxib had no effect on muscular mechanical hyperalgesia, when orally administered 24 h after lengthening contractions." | 1.51 | Nonsteroidal anti-inflammatory drugs and acetaminophen ameliorate muscular mechanical hyperalgesia developed after lengthening contractions via cyclooxygenase-2 independent mechanisms in rats. ( Mikoshiba, S; Shimodaira, T; Taguchi, T, 2019) |
"The prevention of this hyperalgesia by diclofenac (1-10μg), the inhibitors of COX-1 SC-560 (0." | 1.46 | Hyperalgesic and hypoalgesic mechanisms evoked by the acute administration of CCL5 in mice. ( Álvarez, MG; Baamonde, A; Cernuda-Cernuda, R; Fernández-García, MT; Folgueras, AR; García-Domínguez, M; González-Rodríguez, S; Hidalgo, A; Lastra, A; Menéndez, L, 2017) |
"We tested whether this parameter and tactile allodynia, the standard pain measure in preclinical studies, show parallels in their response to analgesics and basic mechanisms." | 1.46 | Grip strength in mice with joint inflammation: A rheumatology function test sensitive to pain and analgesia. ( Cañizares, FJ; Cobos, EJ; Entrena, JM; Fernández-Segura, E; Montilla-García, Á; Perazzoli, G; Portillo-Salido, E; Tejada, MÁ, 2017) |
"Formalin (0." | 1.42 | Celecoxib reduces hyperalgesia and tactile allodynia in diabetic rats. ( Bermúdez-Ocaña, DY; Ble-Castillo, JL; Díaz-Zagoya, JC; Granados-Soto, V; Juárez-Rojop, IE; Morales-Hernández, PE; Torres-Lopez, JE; Tovilla-Zárate, CA, 2015) |
"In a diabetic neuropathic pain model, pretreatment with celecoxib, L-NIL and 7-Ni, significantly increased the antihyperalgesic activity of both Met-F-AEA and AM 1241." | 1.42 | Influence of nitric oxide synthase or cyclooxygenase inhibitors on cannabinoids activity in streptozotocin-induced neuropathy. ( Bujalska-Zadrożny, M; de Cordé, A; Pawlik, K, 2015) |
"Mechanical allodynia and thermal hyperalgesia induced by CCI were markedly attenuated by celecoxib from 5 to 14 days after surgery, and relieved by ibuprofen treatment from 7 to 10 days after surgery." | 1.36 | Cyclooxygenase inhibitors suppress the expression of P2X(3) receptors in the DRG and attenuate hyperalgesia following chronic constriction injury in rats. ( Guo, QL; Huang, CS; Wang, Y; Yan, JQ; Zhang, X; Zou, WY, 2010) |
"Indomethacin (sc) reversed CG-induced hyperalgesia only to basal levels (an anti-hyperalgesic effect)." | 1.36 | Peripheral mu-, kappa- and delta-opioid receptors mediate the hypoalgesic effect of celecoxib in a rat model of thermal hyperalgesia. ( Bakhle, YS; Correa, JD; Dos Reis, WG; Ferreira-Alves, DL; Francischi, JN; Paiva-Lima, P; Rezende, RM, 2010) |
"However, lumiracoxib only produced anti-hyperalgesia." | 1.36 | Is the sulphonamide radical in the celecoxib molecule essential for its analgesic activity? ( Bakhle, YS; de Francischi, JN; dos Reis, WG; Ferreira-Alves, DL; Gassani, BC; Paiva-Lima, P; Rezende, RM, 2010) |
"Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2)." | 1.36 | Celecoxib induces tolerance in a model of peripheral inflammatory pain in rats. ( Bakhle, YS; Camêlo, VM; de Francischi, JN; Dos Reis, WG; Paiva-Lima, P; Rezende, RM, 2010) |
"Swelling and mechanical and thermal hyperalgesia were assessed before and for 28 days after the onset of arthritis." | 1.34 | Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade. ( Anand, P; Essex, D; Feldmann, M; Inglis, JJ; Notley, CA; Williams, R; Wilson, AW, 2007) |
"Celecoxib abrogated carrageenan-induced hyperalgesia in the hind paw accompanied by a decrease in PGE2 content in paw exudates and cerebrospinal fluid in a dose-related manner, with an ED30 = 0." | 1.33 | Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor. ( Fukunaga, M; Hayashi, A; Kimoto, A; Kobayashi, S; Miyata, K; Noguchi, M; Sasamata, M; Yoshino, T, 2005) |
"CION caused ipsilateral cold hyperalgesia between Days 2 and 12, which peaked on Days 4 (sham 15." | 1.33 | Orofacial cold hyperalgesia due to infraorbital nerve constriction injury in rats: reversal by endothelin receptor antagonists but not non-steroidal anti-inflammatory drugs. ( Chichorro, JG; Rae, GA; Souza, GE; Zampronio, AR, 2006) |
"Paw edema and hyperalgesia were monitored from day zero to day 21 after induction as signs of arthritis development." | 1.32 | Role of endogenous glucocorticoids in hyperalgesia and edema in old arthritic rats. ( Alves, DL; Francischi, JN; Pereira, LS; Tatsuo, MA; Yokoro, CM, 2003) |
"3." | 1.32 | Pharmacological characterisation of a rat model of incisional pain. ( Boulet, J; Gottshall, S; Harrison, J; Mark, L; Pearson, M; Walker, K; Whiteside, GT, 2004) |
"Ibuprofen treatment reversed PGE2 levels in injured nerves and DRG, whereas celecoxib blocked increased PGE2 levels only in nerves." | 1.32 | Cyclooxygenase inhibition in nerve-injury- and TNF-induced hyperalgesia in the rat. ( Marziniak, M; Schäfers, M; Sommer, C; Sorkin, LS; Yaksh, TL, 2004) |
"In addition, formalin-induced secondary hyperalgesia was locally prevented by pre-but not post-celecoxib treatment." | 1.32 | Prevention by celecoxib of secondary hyperalgesia induced by formalin in rats. ( Avila, MN; da Motta, PG; Duarte, ID; Francischi, JN; Tatsuo, MA; Veiga, AP, 2004) |
"2." | 1.31 | Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. ( Bakhle, YS; Chaves, CT; Ferreira-Alves, DL; Francischi, JN; Lima, AS; Moura, AC; Rocha, OA, 2002) |
" Both exhibit good oral bioavailability and are potent in standard models of pain, fever, and inflammation yet have a much reduced effect on the GI integrity of rats compared to standard nonsteroidal antiflammatory drugs." | 1.30 | 2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors. ( Black, WC; Brideau, C; Chan, CC; Charleson, S; Chauret, N; Claveau, D; Ethier, D; Gordon, R; Greig, G; Guay, J; Hughes, G; Jolicoeur, P; Leblanc, Y; Nicoll-Griffith, D; Ouimet, N; Prasit, P; Riendeau, D; Visco, D; Wang, Z; Xu, L, 1999) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (5.88) | 18.2507 |
2000's | 19 (37.25) | 29.6817 |
2010's | 25 (49.02) | 24.3611 |
2020's | 4 (7.84) | 2.80 |
Authors | Studies |
---|---|
Penning, TD | 1 |
Talley, JJ | 2 |
Bertenshaw, SR | 1 |
Carter, JS | 1 |
Collins, PW | 1 |
Docter, S | 1 |
Graneto, MJ | 1 |
Lee, LF | 1 |
Malecha, JW | 1 |
Miyashiro, JM | 1 |
Rogers, RS | 1 |
Rogier, DJ | 1 |
Yu, SS | 1 |
Burton, EG | 1 |
Cogburn, JN | 1 |
Gregory, SA | 1 |
Koboldt, CM | 2 |
Perkins, WE | 1 |
Seibert, K | 2 |
Veenhuizen, AW | 1 |
Zhang, YY | 1 |
Isakson, PC | 2 |
Black, WC | 1 |
Brideau, C | 1 |
Chan, CC | 1 |
Charleson, S | 1 |
Chauret, N | 1 |
Claveau, D | 1 |
Ethier, D | 1 |
Gordon, R | 1 |
Greig, G | 1 |
Guay, J | 1 |
Hughes, G | 1 |
Jolicoeur, P | 1 |
Leblanc, Y | 1 |
Nicoll-Griffith, D | 1 |
Ouimet, N | 1 |
Riendeau, D | 1 |
Visco, D | 1 |
Wang, Z | 1 |
Xu, L | 1 |
Prasit, P | 1 |
Szabó, G | 1 |
Fischer, J | 1 |
Kis-Varga, A | 1 |
Gyires, K | 1 |
Lacerda, RB | 1 |
de Lima, CK | 1 |
da Silva, LL | 1 |
Romeiro, NC | 1 |
Miranda, AL | 1 |
Barreiro, EJ | 1 |
Fraga, CA | 1 |
Biava, M | 2 |
Porretta, GC | 1 |
Poce, G | 2 |
Battilocchio, C | 2 |
Alfonso, S | 2 |
Rovini, M | 1 |
Valenti, S | 1 |
Giorgi, G | 1 |
Calderone, V | 2 |
Martelli, A | 2 |
Testai, L | 2 |
Sautebin, L | 2 |
Rossi, A | 2 |
Papa, G | 1 |
Ghelardini, C | 2 |
Di Cesare Mannelli, L | 2 |
Giordani, A | 2 |
Anzellotti, P | 1 |
Bruno, A | 1 |
Patrignani, P | 2 |
Anzini, M | 2 |
Consalvi, S | 1 |
Di Capua, A | 1 |
Persiani, S | 1 |
Colovic, M | 1 |
Dovizio, M | 1 |
Parsons, WH | 1 |
Calvo, RR | 1 |
Cheung, W | 1 |
Lee, YK | 1 |
Patel, S | 1 |
Liu, J | 1 |
Youngman, MA | 1 |
Dax, SL | 1 |
Stone, D | 1 |
Qin, N | 1 |
Hutchinson, T | 1 |
Lubin, ML | 1 |
Zhang, SP | 1 |
Finley, M | 1 |
Liu, Y | 1 |
Brandt, MR | 1 |
Flores, CM | 1 |
Player, MR | 1 |
Singh, P | 3 |
Prasher, P | 1 |
Dhillon, P | 1 |
Bhatti, R | 3 |
Lobo, MM | 1 |
Oliveira, SM | 1 |
Brusco, I | 1 |
Machado, P | 1 |
Timmers, LF | 1 |
de Souza, ON | 1 |
Martins, MA | 1 |
Bonacorso, HG | 1 |
Dos Santos, JM | 1 |
Canova, B | 1 |
da Silva, TV | 1 |
Zanatta, N | 1 |
Kaur, S | 2 |
Kumari, P | 2 |
Kaur, B | 1 |
Kaur, M | 1 |
Singh, G | 1 |
Bhatti, M | 1 |
Kaur, J | 1 |
Felipe, JL | 1 |
Bonfá, IS | 1 |
Lossavaro, PKMB | 1 |
Lencina, JS | 1 |
B Carvalho, D | 1 |
Candeloro, L | 1 |
Ferreira, GIS | 1 |
das Neves, AR | 1 |
Souza, MIL | 1 |
Silva-Filho, SE | 1 |
Baroni, ACM | 1 |
Toffoli-Kadri, MC | 1 |
Shimodaira, T | 1 |
Mikoshiba, S | 1 |
Taguchi, T | 1 |
Crivelaro do Nascimento, G | 1 |
Ferrari, DP | 1 |
Guimaraes, FS | 1 |
Del Bel, EA | 1 |
Bortolanza, M | 1 |
Ferreira-Junior, NC | 1 |
Craft, RM | 1 |
Hewitt, KA | 1 |
Britch, SC | 1 |
Zhao, YQ | 1 |
Wang, HY | 1 |
Yin, JB | 1 |
Sun, Y | 1 |
Wang, Y | 2 |
Liang, JC | 1 |
Guo, XJ | 1 |
Tang, K | 1 |
Wang, YT | 1 |
Montilla-García, Á | 1 |
Tejada, MÁ | 1 |
Perazzoli, G | 1 |
Entrena, JM | 1 |
Portillo-Salido, E | 1 |
Fernández-Segura, E | 1 |
Cañizares, FJ | 1 |
Cobos, EJ | 1 |
Gou, Y | 1 |
Tian, F | 1 |
Dai, M | 1 |
Li, H | 1 |
Lv, Q | 1 |
Kong, Q | 1 |
Chen, T | 1 |
Shao, L | 1 |
Song, H | 1 |
Zhang, Y | 2 |
Zhang, L | 1 |
Lee, JY | 2 |
Choi, HY | 1 |
Park, CS | 1 |
Jang, C | 1 |
Lee, KT | 1 |
Youn, I | 1 |
Yune, TY | 1 |
Tomić, MA | 2 |
Micov, AM | 2 |
Stepanović-Petrović, RM | 2 |
Kovacevic, JM | 1 |
Boškovic, BD | 1 |
Bujalska-Zadrożny, M | 1 |
de Cordé, A | 1 |
Pawlik, K | 1 |
Juárez-Rojop, IE | 1 |
Morales-Hernández, PE | 1 |
Tovilla-Zárate, CA | 1 |
Bermúdez-Ocaña, DY | 1 |
Torres-Lopez, JE | 1 |
Ble-Castillo, JL | 1 |
Díaz-Zagoya, JC | 1 |
Granados-Soto, V | 1 |
Qureshi, RA | 1 |
Tian, Y | 1 |
McDonald, MK | 1 |
Capasso, KE | 1 |
Douglas, SR | 1 |
Gao, R | 1 |
Orlova, IA | 1 |
Barrett, JE | 1 |
Ajit, SK | 1 |
Sacan, A | 1 |
van Helmond, N | 1 |
Steegers, MA | 1 |
Filippini-de Moor, GP | 1 |
Vissers, KC | 1 |
Wilder-Smith, OH | 1 |
González-Rodríguez, S | 1 |
Álvarez, MG | 1 |
García-Domínguez, M | 1 |
Lastra, A | 1 |
Cernuda-Cernuda, R | 1 |
Folgueras, AR | 1 |
Fernández-García, MT | 1 |
Hidalgo, A | 1 |
Baamonde, A | 1 |
Menéndez, L | 1 |
Mi, WL | 1 |
Mao-Ying, QL | 1 |
Liu, Q | 1 |
Wang, XW | 1 |
Wang, YQ | 1 |
Wu, GC | 1 |
Futaki, N | 1 |
Harada, M | 1 |
Sugimoto, M | 1 |
Hashimoto, Y | 1 |
Honma, Y | 1 |
Arai, I | 1 |
Nakaike, S | 1 |
Hoshi, K | 1 |
Zhang, X | 1 |
Guo, QL | 1 |
Zou, WY | 1 |
Huang, CS | 1 |
Yan, JQ | 1 |
Correa, JD | 1 |
Paiva-Lima, P | 3 |
Rezende, RM | 3 |
Dos Reis, WG | 3 |
Ferreira-Alves, DL | 3 |
Bakhle, YS | 4 |
Francischi, JN | 4 |
Gassani, BC | 1 |
de Francischi, JN | 2 |
Camêlo, VM | 1 |
Mohy El-Din, MM | 1 |
Senbel, AM | 1 |
Bistawroos, AA | 1 |
El-Mallah, A | 1 |
Nour El-Din, NA | 1 |
Bekhit, AA | 1 |
Abd El Razik, HA | 1 |
Robinson, I | 1 |
Sargent, B | 1 |
Hatcher, JP | 1 |
Mills, CD | 1 |
Nguyen, T | 1 |
Tanga, FY | 1 |
Zhong, C | 1 |
Gauvin, DM | 1 |
Mikusa, J | 1 |
Gomez, EJ | 1 |
Salyers, AK | 1 |
Bannon, AW | 1 |
Bianchi, M | 1 |
Broggini, M | 1 |
Chaves, CT | 1 |
Moura, AC | 1 |
Lima, AS | 1 |
Rocha, OA | 1 |
Yokoro, CM | 1 |
Tatsuo, MA | 2 |
Pereira, LS | 1 |
Alves, DL | 1 |
Chacur, M | 1 |
Longo, I | 2 |
Picolo, G | 1 |
Gutiérrez, JM | 1 |
Lomonte, B | 1 |
Guerra, JL | 1 |
Teixeira, CF | 1 |
Cury, Y | 2 |
Whiteside, GT | 1 |
Harrison, J | 1 |
Boulet, J | 1 |
Mark, L | 1 |
Pearson, M | 1 |
Gottshall, S | 1 |
Walker, K | 1 |
Schäfers, M | 1 |
Marziniak, M | 1 |
Sorkin, LS | 1 |
Yaksh, TL | 1 |
Sommer, C | 1 |
Hsueh, SF | 1 |
Lu, CY | 1 |
Chao, CS | 1 |
Tan, PH | 1 |
Huang, YW | 1 |
Hsieh, SW | 1 |
Hsiao, HT | 1 |
Chung, NC | 1 |
Lin, SH | 1 |
Huang, PL | 1 |
Lyu, PC | 1 |
Yang, LC | 1 |
Zanchet, EM | 1 |
Veiga, AP | 1 |
Duarte, ID | 1 |
Avila, MN | 1 |
da Motta, PG | 1 |
Yoshino, T | 1 |
Kimoto, A | 1 |
Kobayashi, S | 1 |
Noguchi, M | 1 |
Fukunaga, M | 1 |
Hayashi, A | 1 |
Miyata, K | 1 |
Sasamata, M | 1 |
Chichorro, JG | 1 |
Zampronio, AR | 1 |
Souza, GE | 1 |
Rae, GA | 1 |
Okumura, T | 1 |
Sakakibara, A | 1 |
Murata, Y | 1 |
Kita, Y | 1 |
Inglis, JJ | 1 |
Notley, CA | 1 |
Essex, D | 1 |
Wilson, AW | 1 |
Feldmann, M | 1 |
Anand, P | 1 |
Williams, R | 1 |
Lee, IO | 1 |
Seo, Y | 1 |
Smith, CJ | 1 |
Muhammad, J | 1 |
Zweifel, BS | 1 |
Shaffer, A | 1 |
Masferrer, JL | 1 |
Mazario, J | 1 |
Gaitan, G | 1 |
Herrero, JF | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
In Vivo Selectivity of Cyclooxygenase Inhibitors in the Oral Surgery Model[NCT00006299] | Phase 2 | 120 participants | Interventional | 1999-12-31 | Completed | ||
Pain Modulation in RA - Influence of Adalimumab. A Randomized, Placebo-controlled Study Using Functional Magnetic Resonance Imaging (PARADE)[NCT01197144] | 70 participants (Actual) | Interventional | 2010-10-31 | Completed | |||
Cytokine Responses to Acute Inflammation in the Oral Surgery Model[NCT00006175] | 160 participants | Observational | 2000-08-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
2 trials available for celecoxib and Allodynia
Article | Year |
---|---|
Hyperalgesia and Persistent Pain after Breast Cancer Surgery: A Prospective Randomized Controlled Trial with Perioperative COX-2 Inhibition.
Topics: Adult; Aged; Breast Neoplasms; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; | 2016 |
Anti-hyperalgesic effects of nimesulide: studies in rats and humans.
Topics: Aged; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; | 2002 |
49 other studies available for celecoxib and Allodynia
Article | Year |
---|---|
Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Carrageenan; Celecoxib; Cyclooxygenase 1; C | 1997 |
2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors.
Topics: Analgesics, Non-Narcotic; Animals; Arthritis, Experimental; Biological Availability; Carrageenan; Ce | 1999 |
New celecoxib derivatives as anti-inflammatory agents.
Topics: Acetic Acid; Animals; Carrageenan; Celecoxib; Chronic Disease; Crystallization; Cyclooxygenase 1; Cy | 2008 |
Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Cell Line; Cyclooxygenase 2 Inhibitors; Disease Model | 2009 |
Novel analgesic/anti-inflammatory agents: diarylpyrrole acetic esters endowed with nitric oxide releasing properties.
Topics: Acetates; Animals; Cell Line; Constriction, Pathologic; Cyclooxygenase 2 Inhibitors; Edema; Esters; | 2011 |
Enhancing the pharmacodynamic profile of a class of selective COX-2 inhibiting nitric oxide donors.
Topics: Acetic Acid; Amides; Animals; Carrageenan; Cell Line; Constriction, Pathologic; Cyclooxygenase 2; Cy | 2014 |
Benzo[d]imidazole Transient Receptor Potential Vanilloid 1 Antagonists for the Treatment of Pain: Discovery of trans-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Mavatrep).
Topics: Analgesics; Animals; Benzimidazoles; Biological Availability; Carrageenan; Dogs; Freund's Adjuvant; | 2015 |
Indole based peptidomimetics as anti-inflammatory and anti-hyperalgesic agents: Dual inhibition of 5-LOX and COX-2 enzymes.
Topics: Animals; Anti-Inflammatory Agents; Catalytic Domain; Crystallography, X-Ray; Cyclooxygenase 2 Inhibi | 2015 |
Regioselectively controlled synthesis of 3(5)-(trifluoromethyl)pyrazolylbenzenesulfonamides and their effects on a pathological pain model in mice.
Topics: Animals; Celecoxib; Disease Models, Animal; Edema; Hydrocarbons, Fluorinated; Hyperalgesia; Male; Mi | 2015 |
Tailoring the Substitution Pattern on 1,3,5-Triazine for Targeting Cyclooxygenase-2: Discovery and Structure-Activity Relationship of Triazine-4-Aminophenylmorpholin-3-one Hybrids that Reverse Algesia and Inflammation in Swiss Albino Mice.
Topics: Analgesics; Animals; Carrageenan; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Design; Drug D | 2018 |
Modification of the lead molecule: Tryptophan and piperidine appended triazines reversing inflammation and hyeperalgesia in rats.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 In | 2020 |
1,4-Diaryl-1,2,3-triazole neolignan-celecoxib hybrids inhibit experimental arthritis induced by zymosan.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Celecoxib; Edema; | 2023 |
Nonsteroidal anti-inflammatory drugs and acetaminophen ameliorate muscular mechanical hyperalgesia developed after lengthening contractions via cyclooxygenase-2 independent mechanisms in rats.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Hypera | 2019 |
Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease.
Topics: Amidohydrolases; Analgesics; Animals; Benzamides; Brain; Cannabidiol; Capsaicin; Carbamates; Celecox | 2020 |
Antinociception produced by nonsteroidal anti-inflammatory drugs in female vs male rats.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Disease Models, Animal; Dos | 2021 |
The Analgesic Effects of Celecoxib on the Formalin-induced Short- and Long-term Inflammatory Pain.
Topics: Analgesics; Animals; Celecoxib; Dose-Response Relationship, Drug; Formaldehyde; Hyperalgesia; Male; | 2017 |
Grip strength in mice with joint inflammation: A rheumatology function test sensitive to pain and analgesia.
Topics: Acetaminophen; Analgesics; Animals; Arthritis; Celecoxib; Disease Models, Animal; Diterpenes; Female | 2017 |
Salmon calcitonin exerts better preventive effects than celecoxib on lumbar facet joint degeneration and long-term tactile allodynia in rats.
Topics: Animals; Biomarkers; Calcitonin; Cartilage, Articular; Celecoxib; Hyperalgesia; Image Processing, Co | 2019 |
Inhibition of COX-2 alleviates lumbar spinal stenosis-induced chronic mechanical allodynia in rats.
Topics: Animals; Cauda Equina; Celecoxib; Chronic Pain; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytok | 2019 |
Levetiracetam interacts synergistically with nonsteroidal analgesics and caffeine to produce antihyperalgesia in rats.
Topics: Acetaminophen; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caffeine; Celecoxib; Dr | 2013 |
Antihyperalgesic/antinociceptive effects of ceftriaxone and its synergistic interactions with different analgesics in inflammatory pain in rodents.
Topics: Acetaminophen; Analgesics; Analgesics, Non-Narcotic; Animals; Anti-Bacterial Agents; Ceftriaxone; Ce | 2014 |
Influence of nitric oxide synthase or cyclooxygenase inhibitors on cannabinoids activity in streptozotocin-induced neuropathy.
Topics: Animals; Arachidonic Acids; Cannabinoids; Celecoxib; Cyclooxygenase Inhibitors; Diabetic Neuropathie | 2015 |
Celecoxib reduces hyperalgesia and tactile allodynia in diabetic rats.
Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diabetes Mellitus, Experimental; Dose-Response Rela | 2015 |
Circulating microRNA Signatures in Rodent Models of Pain.
Topics: Animals; Celecoxib; Circulating MicroRNA; Disease Models, Animal; Freund's Adjuvant; Gene Expression | 2016 |
Hyperalgesic and hypoalgesic mechanisms evoked by the acute administration of CCL5 in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemokine CCL5; Cyclooxygenase 2 Inhibi | 2017 |
Synergistic anti-hyperalgesia of electroacupuncture and low dose of celecoxib in monoarthritic rats: involvement of the cyclooxygenase activity in the spinal cord.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Behavior, Animal; Celecox | 2008 |
The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Cel | 2009 |
Cyclooxygenase inhibitors suppress the expression of P2X(3) receptors in the DRG and attenuate hyperalgesia following chronic constriction injury in rats.
Topics: Animals; Celecoxib; Constriction, Pathologic; Cyclooxygenase Inhibitors; Ganglia, Spinal; Hot Temper | 2010 |
Peripheral mu-, kappa- and delta-opioid receptors mediate the hypoalgesic effect of celecoxib in a rat model of thermal hyperalgesia.
Topics: Animals; Carrageenan; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Dose-Response | 2010 |
Is the sulphonamide radical in the celecoxib molecule essential for its analgesic activity?
Topics: Acetazolamide; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationsh | 2010 |
Celecoxib induces tolerance in a model of peripheral inflammatory pain in rats.
Topics: Analgesics; Analysis of Variance; Animals; Celecoxib; Dinoprostone; Hyperalgesia; Indomethacin; Infl | 2010 |
A novel COX-2 inhibitor pyrazole derivative proven effective as an anti-inflammatory and analgesic drug.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Benzenesulfonamides; Carrageenan; Celecoxib; Chronic | 2011 |
Use of dynamic weight bearing as a novel end-point for the assessment of Freund's Complete Adjuvant induced hypersensitivity in mice.
Topics: Adjuvants, Immunologic; Animals; Celecoxib; Chronic Pain; Cyclooxygenase 2 Inhibitors; Endpoint Dete | 2012 |
Characterization of nerve growth factor-induced mechanical and thermal hypersensitivity in rats.
Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Celecoxib; C | 2013 |
Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation.
Topics: Animals; Carrageenan; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhib | 2002 |
Role of endogenous glucocorticoids in hyperalgesia and edema in old arthritic rats.
Topics: Adrenalectomy; Age Factors; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; | 2003 |
Hyperalgesia induced by Asp49 and Lys49 phospholipases A2 from Bothrops asper snake venom: pharmacological mediation and molecular determinants.
Topics: Animals; Bothrops; Bradykinin; Carrageenan; Celecoxib; Crotalid Venoms; Heparin; Hindlimb; Histamine | 2003 |
Pharmacological characterisation of a rat model of incisional pain.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Celecoxib; Cyclohexanecarboxylic Acids; Disease Model | 2004 |
Cyclooxygenase inhibition in nerve-injury- and TNF-induced hyperalgesia in the rat.
Topics: Animals; Behavior, Animal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase | 2004 |
Nonsteroidal anti-inflammatory drugs increase expression of inducible COX-2 isoform of cyclooxygenase in spinal cord of rats with adjuvant induced inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhi | 2004 |
Involvement of spinal neurokinins, excitatory amino acids, proinflammatory cytokines, nitric oxide and prostanoids in pain facilitation induced by Phoneutria nigriventer spider venom.
Topics: Animals; Antibodies; Calcitonin Gene-Related Peptide Receptor Antagonists; Celecoxib; Citrates; Cycl | 2004 |
Prevention by celecoxib of secondary hyperalgesia induced by formalin in rats.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Disease Models, A | 2004 |
Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor.
Topics: Animals; Carrageenan; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cy | 2005 |
Orofacial cold hyperalgesia due to infraorbital nerve constriction injury in rats: reversal by endothelin receptor antagonists but not non-steroidal anti-inflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Atrasentan; Bosentan; Carrageenan; Celecoxib; Cold | 2006 |
Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA.
Topics: Animals; Carrageenan; Celecoxib; Chlorobenzoates; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Din | 2008 |
Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade.
Topics: Animals; Arthritis; Astrocytes; Behavior, Animal; Celecoxib; Collagen; Cyclooxygenase Inhibitors; Di | 2007 |
The effects of intrathecal cyclooxygenase-1, cyclooxygenase-2, or nonselective inhibitors on pain behavior and spinal Fos-like immunoreactivity.
Topics: Animals; Behavior, Animal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitor | 2008 |
Pharmacological analysis of cyclooxygenase-1 in inflammation.
Topics: Animals; Arthritis, Experimental; Blood Platelets; Carrageenan; Celecoxib; Cyclooxygenase 1; Cycloox | 1998 |
Cyclooxygenase-1 vs. cyclooxygenase-2 inhibitors in the induction of antinociception in rodent withdrawal reflexes.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Celecoxib; Cy | 2001 |